Lycia’s $318 Million IPO Pops in Its Debut, Testing Wall Street’s Appetite for Protein Degraders

Lycia Therapeutics, a developer of medicines that pull disease-causing proteins out of circulation, raised about $317.5 million in an upsized initial public offering and saw its shares jump on their first day of trading on the Nasdaq. The deal is one of the larger biotech IPOs of 2026 and a fresh read on how much investors will pay for early-stage science in a nervous market.

The deal terms

Lycia sold 17.64 million shares at $18 each, the top of its indicated range, according to Investing.com, up from roughly 14.7 million shares originally planned. Underwriters have an option to buy about 2.65 million additional shares. Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities ran the books. The stock trades under the ticker LYCA on the Nasdaq Global Select Market.

Trading opened on Friday, Oct. 23. Investing.com reported an opening price of $28.55, a gain of nearly 59 percent over the offering price, before the stock pared some gains to about $23.89 by midday. In a regulatory announcement on Monday, investor RTW Biotech Opportunities said Lycia’s shares closed their first session at $30, up 67 percent. Intraday percentages in other early reports varied, which is typical for a volatile first session; the offering price and share count are consistent across every account reviewed.

What Lycia is building

Lycia develops lysosomal targeting chimeras, or LYTACs, molecules designed to grab harmful proteins outside a cell and route them inside to be destroyed. The company was co-founded by Nobel laureate Carolyn Bertozzi, according to BioPharma Dive. That approach differs from the PROTAC degraders already in the clinic, which work on proteins inside cells.

The pipeline is early. BioPharma Dive reports that the lead program, LCA-0061, targets IgE, the antibody behind allergic reactions, and is in Phase 1 with data expected in 2027. A second program, LCA-0321, aims to clear the autoantibodies that drive Graves’ disease and is also in Phase 1 with 2027 data expected. A follow-on IgE candidate, LCA-0062, could start testing soon. Eli Lilly paid $35 million upfront in a 2021 collaboration covering pain and immune diseases.

Before the IPO, Lycia had raised $267 million in venture capital, and Versant Ventures was its largest shareholder at roughly 19 percent. RTW said the IPO price represented a 233 percent step-up from its cost, and HBM Healthcare Investments, another holder, also flagged the listing to its own investors.

The 2026 IPO window in context

Lycia is one of more than two dozen drugmakers to go public this year, and about two-thirds of those offerings have raised more than $250 million, according to BioPharma Dive’s tracking. That skew toward large, well-financed deals has defined the 2026 window: investors are writing big checks, but mostly for companies with deep venture backing and a clear scientific story. Paxton-Digital covered two earlier fall tests of that window, Iambic and Cambridge-based City Therapeutics, this month.

Protein degradation also has fresh validation. In May, U.S. regulators approved vepdegestrant, sold as Veppanu, which BioPharma Dive describes as the first approved PROTAC degrader, for breast cancer. That approval makes it easier for investors to underwrite the broader degrader category, even when a specific platform such as LYTACs is still unproven in late-stage trials.

Paxton-Digital’s Take

Paxton-Digital reads the Lycia debut as a signal that the IPO window for healthcare is open for a specific kind of company: one with a Nobel-linked platform, a pharma partner, nine-figure venture backing and a pipeline aimed at large markets such as food allergy. It is less clear the window is open for everyone. A first-day pop on a top-of-range, upsized deal says demand exceeded supply for this name; it says little about the next small-cap listing.

The risk profile has not changed because the stock rose. Both clinical programs are in Phase 1, with no efficacy data expected until 2027. Early IPO gains in biotech can reverse quickly once lockups expire or trial readouts disappoint. For acquirers, however, a well-capitalized public degrader company becomes easier to value, and large pharma has spent 2026 licensing and buying pipelines rather than building them. Lycia’s existing Lilly relationship is worth watching on that front.

What it means for you

• If you invest in biotech: compare any purchase to the $18 offering price, not the first-day high. Early buyers at the open paid a large premium for a company with no late-stage data.
• If you follow food allergy treatment: Lycia’s IgE programs are years from any approval decision; Phase 1 data is expected in 2027.
• If you work in Boston-area biotech: a strong reception for large, venture-backed deals may encourage other private companies to file before year end.
• If you are a founder: the 2026 market rewards scale; most successful sector IPOs this year raised more than $250 million.